RayzeBio develops targeted radiopharmaceutical drugs that utilize radioisotopes to deliver treatment directly to solid tumors, including metastatic cancer. By focusing on precise drug delivery, the company aims to improve survival rates for cancer patients through its robust pipeline of drug candidates in various stages of clinical development.
Funding
$160M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SIWMFounders
Product
Problem
Many solid tumors, including metastatic cancers, are difficult to treat effectively with conventional therapies due to their location and resistance to systemic treatments. Traditional radiation therapy can also damage healthy tissue surrounding the tumor.
Solution
RayzeBio is developing targeted radiopharmaceutical drugs that deliver radioisotopes directly to solid tumors, including metastatic disease, to selectively kill cancer cells. This approach aims to improve cancer patient survival by focusing on precise drug delivery, minimizing damage to surrounding healthy tissue. The company leverages a data-driven approach to drug discovery and development, conducting rigorous preclinical evaluation and early human imaging studies to guide patient selection and clinical development. RayzeBio has built a diverse portfolio of radiopharmaceutical drug candidates ranging from discovery to late-stage clinical programs.
Target Audience
The primary target audience is cancer patients with solid tumors, including metastatic disease, and the oncologists who treat them.
Features
- Targeted delivery of radioisotopes directly to solid tumors.
- Diverse pipeline of radiopharmaceutical drug candidates in various stages of clinical development.
- Systematic, data-driven approach to drug discovery and development.
- Rigorous preclinical evaluation and early human imaging studies to guide patient selection.
- Focus on improving cancer patient survival through efficient development of targeted innovative drugs.